Sandip Chaugai1, Wen Yeng Meng2, Amir Ali Sepehry3. 1. Department of Internal Medicine, Institute of Hypertension, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China sandip_schaugai@hotmail.com. 2. Department of Internal Medicine, Institute of Hypertension, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 3. Graduate Program in Neuroscience, College for Interdisciplinary Studies, University of British Columbia, Vancouver, British Columbia, Canada Department of Medicine, Division of Neurology, University of British Columbia, Vancouver, Canada.
Abstract
BACKGROUND: Impact of atrial fibrillation on clinical outcomes is well recognized, and application of renin-angiotensin-aldosterone system (RAAS) blockers for the prevention of atrial fibrillation (AF) is a theoretically appealing concept. However, clinical trials have yielded inconsistent results. METHODS: A pooled study of 26 randomized controlled trials (RCTs) assessing the efficacy of RAAS blockers on AF prophylaxis was performed. RESULTS: A total of 28 reports from 26 randomized controlled trials enrolled 165 387 patients, with an overall 24% reduction in the incidence of AF (odds ratio [OR]: 0.76, 95% confidence interval [CI]: 0.68-0.85], P = .000). Forty-nine percent reduction in the incidence of AF (OR: 0.51, 95% CI: 0.30-0.85, P = .010) in systolic heart failure was observed, whereas no significant effect was observed in patients with diastolic heart failure, postmyocardial infarction, and high cardiovascular disease risk. There was a 19% (OR: 0.81, 95% CI: 0.67-1.00, P = .037) reduction in new-onset and 54% (OR: 0.46, 95% CI: 0.33-0.62, P = .000) reduction in recurrent AF in hypertensive patients with 39% (OR: 0.61, 95% CI: 0.44-0.84, P = .003) risk reduction against calcium blockers and 41% (OR: 0.59, 95% CI: 0.44-0.80, P = .001) risk reduction against β blockers. Angiotensin-receptor blocker appeared marginally superior to angiotensin-converting enzyme inhibitor in primary and secondary prevention. CONCLUSION: This study suggests that RAAS blockade effectively suppresses AF in systolic heart failure, and hypertensives derive greater benefit against new-onset and recurrent AF compared to β blockers, calcium channel blockers, and diuretics.
BACKGROUND: Impact of atrial fibrillation on clinical outcomes is well recognized, and application of renin-angiotensin-aldosterone system (RAAS) blockers for the prevention of atrial fibrillation (AF) is a theoretically appealing concept. However, clinical trials have yielded inconsistent results. METHODS: A pooled study of 26 randomized controlled trials (RCTs) assessing the efficacy of RAAS blockers on AF prophylaxis was performed. RESULTS: A total of 28 reports from 26 randomized controlled trials enrolled 165 387 patients, with an overall 24% reduction in the incidence of AF (odds ratio [OR]: 0.76, 95% confidence interval [CI]: 0.68-0.85], P = .000). Forty-nine percent reduction in the incidence of AF (OR: 0.51, 95% CI: 0.30-0.85, P = .010) in systolic heart failure was observed, whereas no significant effect was observed in patients with diastolic heart failure, postmyocardial infarction, and high cardiovascular disease risk. There was a 19% (OR: 0.81, 95% CI: 0.67-1.00, P = .037) reduction in new-onset and 54% (OR: 0.46, 95% CI: 0.33-0.62, P = .000) reduction in recurrent AF in hypertensivepatients with 39% (OR: 0.61, 95% CI: 0.44-0.84, P = .003) risk reduction against calcium blockers and 41% (OR: 0.59, 95% CI: 0.44-0.80, P = .001) risk reduction against β blockers. Angiotensin-receptor blocker appeared marginally superior to angiotensin-converting enzyme inhibitor in primary and secondary prevention. CONCLUSION: This study suggests that RAAS blockade effectively suppresses AF in systolic heart failure, and hypertensives derive greater benefit against new-onset and recurrent AF compared to β blockers, calcium channel blockers, and diuretics.
Authors: Erik Holzwirth; Jelena Kornej; Sandra Erbs; Danilo Obradovic; Andreas Bollmann; Gerhard Hindricks; Holger Thiele; Petra Büttner Journal: Clin Res Cardiol Date: 2019-06-24 Impact factor: 5.460
Authors: Elsayed Z Soliman; George Howard; Suzanne Judd; Prashant D Bhave; Virginia J Howard; David M Herrington Journal: Am J Cardiol Date: 2020-02-08 Impact factor: 2.778
Authors: Marat Fudim; Peter R Liu; Peter Shrader; Rosalia G Blanco; Larry A Allen; Gregg C Fonarow; Bernard J Gersh; Peter R Kowey; Kenneth W Mahaffey; Elaine Hylek; Alan S Go; Laine Thomas; Eric D Peterson; Jonathan P Piccini Journal: J Am Heart Assoc Date: 2018-04-13 Impact factor: 5.501
Authors: Nathan C Denham; Charles M Pearman; Jessica L Caldwell; George W P Madders; David A Eisner; Andrew W Trafford; Katharine M Dibb Journal: Front Physiol Date: 2018-10-04 Impact factor: 4.566